Drugs that block voltage-gated sodium channels are efficacious in the management of neuropathic pain. Accordingly, this class of ion channels has been a major focus of analgesic research both in academia and in the pharmaceutical/biotechnology industry. In this article, we review the history of the
Discovery of a novel class of biphenyl pyrazole sodium channel blockers for treatment of neuropathic pain
β Scribed by Sriram Tyagarajan; Prasun K. Chakravarty; Bishan Zhou; Brett Taylor; Ronsar Eid; Michael H. Fisher; William H. Parsons; Mathew J. Wyvratt; Kathryn A. Lyons; Tracy Klatt; Xiaohua Li; Sanjeev Kumar; Brande Williams; John Felix; Birgit T. Priest; Richard M. Brochu; Vivien Warren; McHardy Smith; Maria Garcia; Gregory J. Kaczorowski; William J. Martin; Catherine Abbadie; Erin McGowan; Nina Jochnowitz; Ann Weber; Joseph L. Duffy
- Publisher
- Elsevier Science
- Year
- 2010
- Tongue
- English
- Weight
- 444 KB
- Volume
- 20
- Category
- Article
- ISSN
- 0960-894X
No coin nor oath required. For personal study only.
β¦ Synopsis
A series of novel biphenyl pyrazole dicarboxamides were identified as potential sodium channel blockers for treatment of neuropathic pain. Compound 20 had outstanding efficacy in the Chung rat spinal nerve ligation (SNL) model of neuropathic pain.
π SIMILAR VOLUMES
## Abstract For Abstract see ChemInform Abstract in Full Text.
## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a βFull Textβ option. The original article is trackable v
## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
## Abstract A series of azaaromatic quaternary ammonium analogues, e.g. (I) and (II), is discovered as potent and selective Ξ±9Ξ±10 nicotinic acetylcholine receptor (nAChR) antagonists.